Literature DB >> 3415895

The morphine hydrogel suppository. A new sustained release rectal preparation.

C D Hanning1, A P Vickers, G Smith, N B Graham, M E McNeil.   

Abstract

The morphine hydrogel suppository (MHS), a monolithic sustained release rectal preparation, has been developed and evaluated in three pilot studies. Two release profiles have been prepared. The first, MHS(B), has a high initial release rate followed by a constant release for the remainder of a 12-h period. The second, MHS(S), has the same constant release rate for 12 h. MHS(B) is intended to attain and maintain analgesic or near analgesic plasma concentrations of morphine, and MHS(S) to maintain that concentration for successive 12-h periods. The pilot studies suggest that MHS may be of value in the management of postoperative pain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415895     DOI: 10.1093/bja/61.2.221

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  6 in total

Review 1.  Management of post-operative pain.

Authors:  G Smith
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

Review 2.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

3.  Further development of a morphine hydrogel suppository.

Authors:  L Cole; C D Hanning; S Robertson; K Quinn
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

Review 4.  Advanced and controlled drug delivery systems in clinical disease management.

Authors:  J R Brouwers
Journal:  Pharm World Sci       Date:  1996-10

Review 5.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  Morphine: pharmacokinetics and clinical practice.

Authors:  P J Hoskin; G W Hanks
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.